Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000734270 | SCV000862395 | uncertain significance | not provided | 2018-07-25 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004027080 | SCV003683009 | uncertain significance | not specified | 2022-08-02 | criteria provided, single submitter | clinical testing | The c.1009G>A (p.D337N) alteration is located in exon 5 (coding exon 5) of the RNF135 gene. This alteration results from a G to A substitution at nucleotide position 1009, causing the aspartic acid (D) at amino acid position 337 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Laboratory of Diagnostic Genome Analysis, |
RCV000734270 | SCV001799138 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000734270 | SCV001968245 | likely benign | not provided | no assertion criteria provided | clinical testing |